Literature DB >> 8824793

Vaccines against human cytomegalovirus: time to test.

W J Britt1.   

Abstract

Infections associated with human cytomegalovirus are an important cause of morbidity and mortality in immunocompromised individuals. Recent studies in humans and animal models have shown that some human cytomegalovirus proteins can induce protective immunity. The availability of recombinant viral proteins means that candidate subunit vaccines can now be tested in clinical trials.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8824793     DOI： 10.1016/0966-842x(96)81503-4

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  7 in total

1.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression.

Authors:  S Pepperl; J Münster; M Mach; J R Harris; B Plachter
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Early stage of cytomegalovirus infection suppresses host microRNA expression regulation in human fibroblasts.

Authors:  Anton A Buzdin; Alina V Artcibasova; Natalya F Fedorova; Maria V Suntsova; Andrew V Garazha; Maxim I Sorokin; Daria Allina; Mikhail Shalatonin; Nikolay M Borisov; Alex A Zhavoronkov; Igor Kovalchuk; Olga Kovalchuk; Alla A Kushch
Journal:  Cell Cycle       Date:  2016-12-16       Impact factor: 4.534

Review 4.  Immediate-Early (IE) gene regulation of cytomegalovirus: IE1- and pp71-mediated viral strategies against cellular defenses.

Authors:  Lilith Torres; Qiyi Tang
Journal:  Virol Sin       Date:  2014-11-25       Impact factor: 4.327

5.  Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues.

Authors:  Nikolaus Wirtz; Sina I Schader; Rafaela Holtappels; Christian O Simon; Niels A W Lemmermann; Matthias J Reddehase; Jürgen Podlech
Journal:  Med Microbiol Immunol       Date:  2008-03-26       Impact factor: 3.402

6.  Host immune responses to a viral immune modulating protein: immunogenicity of viral interleukin-10 in rhesus cytomegalovirus-infected rhesus macaques.

Authors:  Meghan K Eberhardt; W L William Chang; Naomi J Logsdon; Yujuan Yue; Mark R Walter; Peter A Barry
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

7.  N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.

Authors:  Florent Dufour; Thibault Rattier; Sarah Shirley; Gaelle Picarda; Andrei Alexandru Constantinescu; Aymeric Morlé; Al Batoul Zakaria; Guillaume Marcion; Sebastien Causse; Eva Szegezdi; Dirk Michael Zajonc; Renaud Seigneuric; Gilles Guichard; Tijani Gharbi; Fabien Picaud; Guillaume Herlem; Carmen Garrido; Pascal Schneider; Chris Alan Benedict; Olivier Micheau
Journal:  Cell Death Differ       Date:  2017-02-10       Impact factor: 15.828
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.